| Literature DB >> 28378220 |
Małgorzata Pleszczyńska1, Marta K Lemieszek2, Marek Siwulski3, Adrian Wiater4, Wojciech Rzeski2,5, Janusz Szczodrak4.
Abstract
Higher Basidiomycota have been used in natural medicine throughout the world for centuries. One of such fungi is Fomitopsis betulina (formerly Piptoporus betulinus), which causes brown rot of birch wood. Annual white to brownish fruiting bodies of the species can be found on trees in the northern hemisphere but F. betulina can also be cultured as a mycelium and fruiting body. The fungus has a long tradition of being applied in folk medicine as an antimicrobial, anticancer, and anti-inflammatory agent. Probably due to the curative properties, pieces of its fruiting body were carried by Ötzi the Iceman. Modern research confirms the health-promoting benefits of F. betulina. Pharmacological studies have provided evidence supporting the antibacterial, anti-parasitic, antiviral, anti-inflammatory, anticancer, neuroprotective, and immunomodulating activities of F. betulina preparations. Biologically active compounds such as triterpenoids have been isolated. The mushroom is also a reservoir of valuable enzymes and other substances such as cell wall (1→3)-α-D-glucan which can be used for induction of microbial enzymes degrading cariogenic dental biofilm. In conclusion, F. betulina can be considered as a promising source for the development of new products for healthcare and other biotechnological uses.Entities:
Keywords: Biological activity; Cultivation; Fomitopsis betulina; Phytochemistry; Piptoporus betulinus
Mesh:
Substances:
Year: 2017 PMID: 28378220 PMCID: PMC5380686 DOI: 10.1007/s11274-017-2247-0
Source DB: PubMed Journal: World J Microbiol Biotechnol ISSN: 0959-3993 Impact factor: 3.312
Fig. 1Fomitopsis betulina. a Basidiocarp of the wild fungus. b Mycelium on an agar plate. c Mature fruiting body cultured on birch sawdust in artificial conditions. (photographed by M. Siwulski)
Biological properties of extracts and compounds isolated from Fomitopsis betulina
| Biological activity | Mechanism of biological activity | Model [method of study] | Extracta | Active compounda | References |
|---|---|---|---|---|---|
| Bactericidal | Inhibition of bacterial growth |
| Extracts | Suay et al. ( | |
|
| Benzene extracts | Polyporenic acid (suggested) | Utzig and Fertig ( | ||
|
| Chloroform extracts | Karaman et al. ( | |||
|
| Dichloromethane extracts | Keller et al. ( | |||
|
| Methanol extracts | Karaman et al. ( | |||
|
| Ethanol extracts | Polyporenic acid A (suggested) | Kandefer-Szerszeń et al. ( | ||
|
| Ether extracts | Polyporenic acid (suggested) | Kandefer-Szerszeń and Kawecki ( | ||
|
| Piptamine isolated from submerged culture of | Schlegel et al. ( | |||
|
| Mycelium, culture liquid | Krupodorova et al. ( | |||
|
| 3β-acetoxy-16α hydroxyl-24-oxo-5α-lanosta-8-ene-21-oic acid | Alresly et al. ( | |||
|
| Alkali extract | Vunduk et al. ( | |||
| Fungicidal | Inhibition of fungal growth |
| Extracts | Suay et al. ( | |
|
| Piptamine isolated from submerged culture of | Schlegel et al. ( | |||
| Larvicidal | Induction of larva death |
| Dichloromethane extract | Keller et al. ( | |
| Antiviral | Protection of CEF cells from | Host/target cells: primary culture of chick embryo fibroblast (CEF) Challenge virus: | Ethanol extracts | Kandefer-Szerszeń et al. ( | |
| Induction of sub stance with properties similar to interferon (hot-stable, stable at pH 2, nondialyzing, insensitive to RNA-se, slightly sensitive to trypsin) | [Plaque formation assays] | Water extracts | Kandefer-Szerszeń and Kawecki ( | ||
| Ether extracts | polyporenic acid (suggested) | Kandefer-Szerszeń and Kawecki ( | |||
| nucleic acids (RNA and DNA) | Kandefer-Szerszeń et al. ( | ||||
| Protection of HAT cells from | Host/target cells: human fibroblast culture (HAT) challenge virus: [plaque formation assays] | RNA | Kawecki et al. ( | ||
| Mice protection from lethal infection with TBE | Host/target: Swiss mice Challenge virus: | Ethanol extracts | Kandefer-Szerszeń et al. ( | ||
| Water extracts induced substance with properties similar to interferon (stable at pH 2, nondialyzing, sensitive to trypsin) | [Neutralization test] | Water extracts | Kandefer-Szerszeń and Kawecki ( | ||
| Ether extracts | Polyporenic acid | Kandefer-Szerszeń and Kawecki ( | |||
| Nucleic acids (RNA and DNA) (suggested) | Kandefer-Szerszeń et al. ( | ||||
| Mice protection from lethal infection with HSV-2 | host/target: Swiss mice Challenge virus: | RNA | Kawecki et al. ( | ||
| Anti-inflammatory | Angiotensin I-converting enzyme inhibitory activity | Alkali extract | Vunduk et al. ( | ||
| Strong inhibition of 3α-hydroxysteroid dehydrogenase (3α-HSD), hyaluronate lyase and weak inhibition of cyclooxygenase-1 (COX-1) | [Enzyme-based assays: (3α-HSD)-assay according to the method of Penning; N-cetyl-N-trimethylammonium bromide assay according to the method of Ferrante; COX-1 assay] | Polyporenic acid C; (3α,12α,25 S)-12-hydroxy-3-(3-methoxy-1,3- dioxopropoxy)-24-methylene-lanost-8-en-26-oic acid; (3α,12α,25 S)-3-(acetyloxy)-12-hydroxy-24- methylene-lanost-8-en-26-oic acid | Wangun et al. ( | ||
| Mice protection from ear edema induction by 12- | Mice ear edema model | Polyporenic acid A; polyporenic acid C; (3α,12α,25 S)-3-[(carboxyacetyl)oxy]-12-hydroxy-24-methylene-lanost-8-en-26-oic acid; (3α,12α,25 S)-12-hydroxy-3-[[(3 S)-3-hydroxy-5-methoxy-3-methyl-1,5-dioxopentyl]oxy]-24- methylene-lanost-8-en-26-oic acid; (+)-12α,28-dihydroxy-3α-(30-hydroxy-30-methylglutaryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid | Kamo et al. ( | ||
| Antioxidant | Antioxidant capacity | [DPPH scavenging activity, FRAP method] | Water extracts | Vunduk et al. ( | |
| Antioxidant capacity | [DPPH scavenging activity, reducing power, α-carotene bleaching inhibition] | α-, β-, γ-, δ-tocopherols; ascorbic acid; β-carotene; lycopene | Reis et al. ( | ||
| Antioxidant capacity | [FRAP method] | p-hydroxybenzoic acid; protocatechuic acid; vanillic acid | Sułkowska-Ziaja et al. ( | ||
| Immunomodu-lation | Activation of neutrophils to production of reactive oxygen forms | Neutrophils from human peripheral blood [LDCL method] | Water extracts from fruiting bodies and mycelium | Shamtsyan et al. ( | |
| Anticancer | Antimigrative properties | Cancer cell lines: A549, HT-29, T47D, TE671 [wound assay] | Ethanol extracts | Pleszczyńska et al. ( | |
| Cancer cell line:TE671 [wound assay] | Ether extracts | Zwolińska ( | |||
| Cancer cell lines: A549, C6, HT-29, T47D [wound assay] | Water extracts | Pleszczyńska et al. ( | |||
| Cancer cell lines: A549, HT-29, T47D [wound assay] | Water and ethanol extracts of cultivated fruiting bodies | Pleszczyńska et al. ( | |||
| Decrease in tumor cell adhesion | Cancer cell line: LS180 [crystal violet assay] | Ethanol and ether extracts of in vitro grown mycelium | Cyranka et al. ( | ||
| Apoptosis induction | Cancer cell line: T47D [ELISA] | Ethanol extracts | Zwolińska ( | ||
| Cancer cell line: A549 [ELISA] | Ether extracts | Żyła ( | |||
| Cancer cell lines: A549, C6 [ELISA, May Grünwald Giemsa staining] | Water extracts | Lemieszek et al. ( | |||
| Cell death induction | Cancer cell lines: A549, T47D, TE671 [May Grünwald Giemsa staining] | Ethanol extracts | Żyła et al. ( | ||
| Decrease in cancer viability | Cancer cell line: HeLa [MTT test] | carboxymethylated (1→3)- -α-D-glucans | Wiater et al. ( | ||
| Decrease in cancer viability | Cancer cell line: LS180]MTT test] | Ethanol and ether extracts of in vitro grown mycelium | Cyranka et al. ( | ||
| Inhibition of MMP-3, MMP-9, MMP-14 | Cancer cell line: A549 [zymography] | Ethanol and ether extracts | Zwolińska ( | ||
| Inhibition of MMP-9 | Cancer cell line: HT-29 [zymography] | Water extracts | Lemieszek ( | ||
| Inhibition of MMP-1, MMP-3, MMP-9 | [Hydrolysis of MMP protein substrates—labeled synthetic peptides] | (E)-2-(4-hydroxy-3-methyl-2-butenyl)-hydroquinone | Kawagishi et al. ( | ||
| Inhibition of MMP-1 | [Hydrolysis of MMP protein substrates—labeled synthetic peptides] | polyporenic acid C | Kawagishi et al. ( | ||
| Inhibition of cancer cells proliferation | Cancer cell lines: A549, C6, HEp-2, HT-29, Jurkat E6.1, RPMI 8226, T47D, TE671 [MTT test] | Ethanol extracts | Pleszczyńska et al. ( | ||
| Cancer cell lines: A549, HT-29, T47D [MTT test] | Ethanol extracts of cultivated fruiting bodies | Pleszczyńska et al. ( | |||
| Cancer cell lines: A549, C6, FTC238, HEp-2, HeLa, HT-29, Jurkat E6.1, RPMI 8226, SK-N-AS, T47D, TE671 [MTT test] | Ether extract | Wasyl ( | |||
| Cancer cell lines: A549, C6, HT-29, Jurkat E6.1, T47D [MTT test] | Water extracts | Pleszczyńska et al. ( | |||
| Cancer cell lines: A549, HT-29, T47D [MTT test] | Water extracts of cultivated fruiting bodies | Pleszczyńska et al. ( | |||
| Cancer cell lines: A549, T47D [MTT test] | Polyporenic acid A | Zwolińska ( | |||
| Inhibition of DNA synthesis | Cancer cell line: C6 [BrdU test] | Ethanol extracts | Wasyl ( | ||
| Cancer cell lines: A549, C6 [BrdU test] | Water extracts | Lemieszek et al. ( | |||
| Alterations in cell cycle progression—accumulation of cancer cells in the “S” phase | Cancer cell line: FTC238 [flow cytometry] | Ether extract | Kaczor et al. ( | ||
| Inhibition of cancer cell growth | Mouse sarcoma S-37 [not given] | Extracts | Blumenberg and Kessler ( | ||
| Tumor size reduction by induction of cancer cell necrolysis and inhibition of metastases | Female dogs with adenocarcinoma mammae, adenocarcinoma solidum, adenocarcinoma papilliferum [histopathological examination after Hansen staining] | Water extracts | Pentacyclic triterpenes (suggested) | Wandokanty et al. ( | |
| Tumor size reduction and inhibition of bleeding from the genital tract | Female dogs with Sticker’s sarcoma [per vaginal examination] | Ethanol extracts | Pentacyclic triterpenes (suggested) | Utzig and Samborski ( | |
| Neuroprotec-tion | Protection of neurons against damage induced by cisplatine, trophic stress, excitotoxicity | Mouse neurons—10-day old [LDH test] | Ethanol and ether extracts | Wasyl ( |
Cancer cell lines: A549—human Caucasian lung carcinoma, C6—rat glioma, FTC238—human thyroid carcinoma, HeLa—human cervical adenocarcinoma, Hep-2 (HeLa derivative)—human cervix carcinoma, HT-29—human colon adenocarcinoma, Jurkat E6.1—human T-cell leukemia, LS180—human colorectal adenocarcinoma, RPMI 8226—human multiple myeloma, SK-N-AS—human neuroblastoma, T47D—human breast ductal carcinoma, T671—human rhabdomyosarcoma/medulloblastoma
aExtracts/compounds were isolated from fruiting bodies of wild growing F. betulina, unless otherwise indicated
3α-HSD 3-α hydroxysteroid dehydrogenase, BrdU − 5-bromo-2’-deoxyuridine, COX-1 cyclooxygenase-1, DPPH 2,2-diphenyl-1-picrylhydrazyl, ELISA enzyme-linked immunosorbent assay, FRAP ferric ion reducing antioxidant power, LDCL luminol-dependent chemiluminescence, LDH lactate dehydrogenase, MTT methylthiazolyldiphenyl-tetrazolium bromide, NCCLS National Committee for Clinical Laboratory Standards
Fig. 2Chemical structures of bioactive compounds isolated from F. betulina